F11R抗体—艾普蒂

+ +

•  

   

     Gel: 8%SDS-PAGE, Lysate: 40 μg, Lane 1-4: K562 cells, human kidney cancer tissue, 293T cells, HepG2 cells, Primary antibody: P08451(F11R Antibody) at dilution 1/600, Secondary antibody: Goat anti rabbit IgG at 1/8000 dilution, Exposure time: 5 seconds    

  
  

•  

   

     The image is immunohistochemistry of paraffin-embedded Human liver cancer tissue using P08451(F11R Antibody) at dilution 1/60. (Original magnification: ×200)    

  
  

•  

   

     The image is immunohistochemistry of paraffin-embedded Human colon cancer tissue using P08451(F11R Antibody) at dilution 1/60. (Original magnification: ×200)    

  
  

The F11 receptor (F11R), also known as Junctional Adhesion Molecule-A (JAM-A), is a transmembrane protein belonging to the immunoglobulin superfamily. First identified in the late 1990s, it plays critical roles in maintaining cell polarity, regulating tight junction assembly in endothelial and epithelial cells, and mediating leukocyte transmigration during inflammation. Structurally, it features two extracellular Ig-like domains, a single transmembrane region, and a cytoplasmic tail involved in signaling.

F11R/JAM-A interacts with integrins and other ligands, influencing platelet activation, angiogenesis, and immune responses. Dysregulation of F11R is linked to pathologies including atherosclerosis, cancer metastasis, and inflammatory bowel disease. For instance, its overexpression in certain cancers promotes tumor cell adhesion and migration.

Antibodies targeting F11R are valuable tools for studying these mechanisms. They can block ligand binding or disrupt F11R-mediated signaling, enabling researchers to explore its role in disease models. Therapeutic applications are under investigation, particularly in inhibiting cancer progression or modulating inflammatory conditions. However, challenges remain in optimizing specificity and minimizing off-target effects. Current research focuses on developing monoclonal antibodies with enhanced affinity and exploring bispecific designs for combination therapies.